Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.
S Van SteenbergenS BianS VermeireG Van AsscheA GilsMarc FerrantePublished in: Alimentary pharmacology & therapeutics (2017)
Overall, 65% of patients who de-escalated to adalimumab 40 mg every 3 weeks remained in clinical remission for a median of 24 months. In 53% of patients, adalimumab-related adverse events disappeared after dose de-escalation. Regardless of adalimumab SL, disease remission should be assessed objectively prior to dose de-escalation.
Keyphrases
- ulcerative colitis
- rheumatoid arthritis
- juvenile idiopathic arthritis
- disease activity
- end stage renal disease
- open label
- hidradenitis suppurativa
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- physical activity
- systemic lupus erythematosus
- prognostic factors
- randomized controlled trial
- clinical trial
- patient reported outcomes
- study protocol
- drug induced